Company argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per region

Ratings for argenx SE

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Euronext Bruxelles Other stock markets 10:58:35 2024-04-25 am EDT			5-day change	1st Jan Change
348.6 ^EUR	-0.37%		+1.93%	+1.48%

Apr. 17	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 16	Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	CI

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.

Number of employees: 1,148

EUR in Million	2022	Weight	2023	Weight	Delta
Antibody-based Medicines 100.0 %	391	100.0 %	1,134	100.0 %	+190.23%

EUR in Million	2022	Weight	2023	Weight	Delta
United States 87.8 %	359	91.9 %	996	87.8 %	+177.12%
EMEA 5.9 %	-	-	67	5.9 %	-
Japan 4.6 %	15	3.8 %	52	4.6 %	+248.00%
China 1.7 %	4	1.0 %	19	1.7 %	+368.86%

Managers	Title	Age	Since
Tim van Hauwermeiren FOU	Founder	52	07-12-31
Karl Gubitz DFI	Director of Finance/CFO	54	21-05-31
Filip Borgions CTO	Chief Tech/Sci/R&D Officer	-	14-12-31
Karen Massey COO	Chief Operating Officer	45	23-03-12
Peter Ulrichts CTO	Chief Tech/Sci/R&D Officer	44	22-12-31
Luc Truyen CTO	Chief Tech/Sci/R&D Officer	59	22-03-31
Beth Delgiacco IRC	Investor Relations Contact	-	17-12-31
Hemamalini Moorthy LAW	General Counsel	54	22-02-13
Marc Schorpion HRO	Human Resources Officer	66	18-11-30
Arjen Lemmen PRN	Corporate Officer/Principal	39	15-12-31

Members of the board	Title	Age	Since
Anthony Adam Rosenberg BRD	Director/Board Member	71	17-04-25
Joseph deBethizy BRD	Director/Board Member	74	15-05-12
Pamela Klein BRD	Director/Board Member	63	16-04-27
Peter K. M. Verhaeghe CHM	Chairman	66	08-10-14
Tim van Hauwermeiren FOU	Founder	52	07-12-31
James Daly BRD	Director/Board Member	63	18-05-07
Steve Krognes BRD	Director/Board Member	56	23-02-26
Camilla Sylvest BRD	Director/Board Member	52	22-09-07
Ana Cespedes BRD	Director/Board Member	51	22-12-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	59,431,079	59,358,579 ( 99.88 %)	0	99.88 %

Name	Equities	%	Valuation
Federated Global Investment Management Corp. 2.783 %	1,650,263	2.783 %	652 M €
Wellington Management Co. LLP 2.564 %	1,520,216	2.564 %	601 M €
OP Asset Management Ltd. 0.3171 %	188,027	0.3171 %	74 M €
Carmignac Gestion Luxembourg SA (UK) 0.2619 %	155,288	0.2619 %	61 M €
FundQuest Advisor 0.2228 %	132,122	0.2228 %	52 M €
Union Investment Privatfonds GmbH 0.1675 %	99,314	0.1675 %	39 M €
State Street Global Advisors Ltd. 0.1653 %	98,051	0.1653 %	39 M €
BNP Paribas Asset Management Belgium SA 0.1574 %	93,364	0.1574 %	37 M €
Puilaetco Dewaay Private Bankers SA 0.1265 %	75,000	0.1265 %	30 M €
Sjunde AP-fonden 0.1222 %	72,475	0.1222 %	29 M €

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 6.429 %	3,812,372	6.429 %	1 501 M €
T Rowe Price Associates, Inc. (13F Subfiler) 6.195 %	3,673,855	6.195 %	1 446 M €
Artisan Partners Holdings LP 5.353 %	3,174,477	5.353 %	1 250 M €
Artisan Partners LP 5.353 %	3,174,477	5.353 %	1 250 M €
Capital Research & Management Co. (World Investors) 3.307 %	1,961,202	3.307 %	772 M €
Janus Henderson Investors US LLC 2.996 %	1,776,759	2.996 %	700 M €
Avoro Capital Advisor LLC 2.082 %	1,234,567	2.082 %	486 M €
T. Rowe Price Investment Management, Inc. 1.993 %	1,182,121	1.993 %	465 M €
Bellevue Asset Management AG 1.466 %	869,208	1.466 %	342 M €
BlackRock Advisors LLC 1.216 %	720,989	1.216 %	284 M €

argenx SE

Laarderhoogtweg 25

1101 EB, Amsterdam

+31 10 703 8441

http://www.argenx.com

Name	Category and Sector
arGEN-X BV arGEN-X BV Pharmaceuticals: OtherHealth Technology Part of argenx SE, arGEN-X BV is a Belgian company that manufactures antibody-based medicines. The private company is based in Zwijnaarde, Belgium.	Pharmaceuticals: Other

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

349.9 EUR

Average target price

439.3 EUR

Spread / Average Target

+25.55%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ARGENX SE	+1.48%	22.2B
VERTEX PHARMACEUTICALS INCORPORATED	-3.28%	104B
REGENERON PHARMACEUTICALS, INC.	+0.20%	97.42B
BIONTECH SE	-18.27%	21.23B
GENMAB A/S	-10.88%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-17.44%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.76%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.22%	11.66B
LEGEND BIOTECH CORPORATION	-25.72%	8.22B

Bio Therapeutic Drugs